Future-Proofing Human Capital: Does Biopharma Have The Right Stuff?

31 Jul 2017

• By William Looney

Biopharma's future depends entirely on the application of human ingenuity to complex problems with no easy solutions. In Vivo, with its Informa business solutions partner EBD Academy, recently conducted a survey of industry decision-makers in the US and Europe for recommendations on how to attract talent, boost employee engagement, foster diversity and maintain the product innovation that patients demand and society expects.

In an industry with financial margins so high they induce nosebleeds in consumers and policy-makers alike, it’s surprising how little attention is paid to biopharma’s equally vast reserves of human capital. By nearly every indication, the industry and its fellow travelers in the life sciences possess the most productive, knowledge-intensive, highly educated and well-compensated workforce in the world. Nevertheless, this disconnect deserves its own question: can we affirm that all is well in this most comfortable of career destinations?

To find out, In Vivo, together with Informa’s newly launched life sciences learning business, EBD Academy, conducted a comprehensive survey...